Open Payments

ANDREW D. CAMPBELL

Type
Physician · Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology
Where
LANHAM, MD
NPI
1770593303
Received
$100,509 in 119 records, 2019 to 2025 ($93,732 general, $6,777 research)
As principal investigator
$1,880,736 of research payments to others in 62 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment15$4,079
2024General payment12$1,844
2023General payment41$32,946
2022General payment25$19,988
2022Research payment3$5,513
2021General payment9$13,296
2021Research payment1$1,264
2020General payment10$17,730
2019General payment3$3,847

By company

CompanyRecordsAmountYears
GLOBAL BLOOD THERAPEUTICS, INC.18$24,6392020–2022
Novartis Pharmaceuticals Corporation17$21,7552019–2022
VERTEX PHARMACEUTICALS INCORPORATED18$21,1462022–2024
Chiesi USA, Inc.17$18,6132020–2023
Agios Pharmaceuticals, Inc.36$8,8632022–2025
Omeros Corporation1$2,8002020
TerSera Therapeutics LLC1$1,1102022
Novo Nordisk Health Care AG1$6552025
PFIZER INC.6$6182023–2025
Novo Nordisk Inc2$2462024–2025
Genetix Biotherapeutics Inc2$612023

By nature of payment

NatureRecordsAmount
Consulting Fee30$71,762
Honoraria7$9,847
Research payment4$6,777
Compensation for services other than consulting, including serving as faculty or as a speaker at a v6$5,330
Food and Beverage60$4,256
Travel and Lodging12$2,536

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-06Agios Pharmaceuticals, Inc.$140Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2025
2025-12-06Novo Nordisk Inc$121Food and BeverageIn-kind items and services2025
2025-12-05Agios Pharmaceuticals, Inc.$16Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2025
2025-12-05Agios Pharmaceuticals, Inc.$5Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2025
2025-10-24Novo Nordisk Health Care AG$655Consulting FeeCash or cash equivalent2025
2025-10-04Agios Pharmaceuticals, Inc.$49Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2025
2025-10-02Agios Pharmaceuticals, Inc.$1Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2025
2025-10-01Agios Pharmaceuticals, Inc.$147Food and BeverageIn-kind items and services2025
2025-10-01Agios Pharmaceuticals, Inc.$147Food and BeverageIn-kind items and services2025
2025-07-31PFIZER INC.$300Travel and LodgingIn-kind items and services2025
2025-07-31PFIZER INC.$152Food and BeverageIn-kind items and services2025
2025-07-31PFIZER INC.$50Travel and LodgingIn-kind items and services2025
2025-07-11Agios Pharmaceuticals, Inc.$209Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2025
2025-05-13Agios Pharmaceuticals, Inc.$139Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2025
2025-02-07Agios Pharmaceuticals, Inc.$1,942Consulting FeeCash or cash equivalentPYRUKYND Drug, Genetically Defined Disease2025
2024-12-07Agios Pharmaceuticals, Inc.$42Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2024
2024-12-07Agios Pharmaceuticals, Inc.$5Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2024
2024-12-06Novo Nordisk Inc$125Food and BeverageIn-kind items and services2024
2024-12-05Agios Pharmaceuticals, Inc.$23Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2024
2024-10-02Agios Pharmaceuticals, Inc.$6Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2024
2024-09-04VERTEX PHARMACEUTICALS INCORPORATED$21Food and BeverageIn-kind items and servicesCASGEVY Biological, SICKLE CELL DISEASE/BETA THALESSEMIA2024
2024-07-23Agios Pharmaceuticals, Inc.$14Travel and LodgingCash or cash equivalentPYRUKYND Drug, Genetically Defined Disease2024
2024-07-23Agios Pharmaceuticals, Inc.$3Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2024
2024-06-07PFIZER INC.$103Food and BeverageIn-kind items and servicesOXBRYTA Drug, HEMATOLOGY2024
2024-05-23Agios Pharmaceuticals, Inc.$107Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2024
2024-04-11PFIZER INC.$3Food and BeverageIn-kind items and servicesOXBRYTA Drug, HEMATOLOGY2024
2024-01-04Agios Pharmaceuticals, Inc.$1,387HonorariaCash or cash equivalentPYRUKYND Drug, Genetically Defined Disease2024
2023-12-13VERTEX PHARMACEUTICALS INCORPORATED$650Consulting FeeCash or cash equivalent2023
2023-12-07Agios Pharmaceuticals, Inc.$164Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2023
2023-12-07Agios Pharmaceuticals, Inc.$139Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2023
2023-12-06Genetix Biotherapeutics Inc$22Food and BeverageIn-kind items and services2023
2023-10-28Agios Pharmaceuticals, Inc.$11Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2023
2023-10-26Agios Pharmaceuticals, Inc.$46Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2023
2023-10-25Agios Pharmaceuticals, Inc.$60Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2023
2023-10-23Agios Pharmaceuticals, Inc.$43Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2023
2023-08-28VERTEX PHARMACEUTICALS INCORPORATED$6,825Consulting FeeCash or cash equivalent2023
2023-08-23VERTEX PHARMACEUTICALS INCORPORATED$6,825Consulting FeeCash or cash equivalent2023
2023-08-03Chiesi USA, Inc.$1,740Consulting FeeCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-07-31VERTEX PHARMACEUTICALS INCORPORATED$36Food and BeverageIn-kind items and services2023
2023-07-30VERTEX PHARMACEUTICALS INCORPORATED$288Travel and LodgingIn-kind items and services2023
2023-07-27Chiesi USA, Inc.$870Consulting FeeCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-07-26Chiesi USA, Inc.$870Consulting FeeCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-07-13VERTEX PHARMACEUTICALS INCORPORATED$336Travel and LodgingIn-kind items and services2023
2023-07-13VERTEX PHARMACEUTICALS INCORPORATED$64Food and BeverageIn-kind items and services2023
2023-07-13VERTEX PHARMACEUTICALS INCORPORATED$44Food and BeverageIn-kind items and services2023
2023-07-13VERTEX PHARMACEUTICALS INCORPORATED$26Food and BeverageIn-kind items and services2023
2023-07-13VERTEX PHARMACEUTICALS INCORPORATED$26Food and BeverageIn-kind items and services2023
2023-07-12VERTEX PHARMACEUTICALS INCORPORATED$397Travel and LodgingIn-kind items and services2023
2023-07-12VERTEX PHARMACEUTICALS INCORPORATED$141Food and BeverageIn-kind items and services2023
2023-06-17Agios Pharmaceuticals, Inc.$31Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2023
2023-05-18Agios Pharmaceuticals, Inc.$65Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2023
2023-05-15Chiesi USA, Inc.$870Consulting FeeCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-05-15Chiesi USA, Inc.$870Consulting FeeCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-05-14Chiesi USA, Inc.$870Consulting FeeCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-05-11Chiesi USA, Inc.$870Consulting FeeCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-05-10Chiesi USA, Inc.$870Consulting FeeCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-05-10PFIZER INC.$7Food and BeverageIn-kind items and servicesOXBRYTA Drug, HEMATOLOGY2023
2023-04-12Genetix Biotherapeutics Inc$38Food and BeverageIn-kind items and servicesZynteglo Drug, beta-thalassemia2023
2023-02-15Agios Pharmaceuticals, Inc.$114Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2023
2023-01-29Chiesi USA, Inc.$7,500Consulting FeeCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-01-29Chiesi USA, Inc.$156Food and BeverageCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-01-29Chiesi USA, Inc.$84Travel and LodgingCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-01-29Chiesi USA, Inc.$45Travel and LodgingCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-01-28Chiesi USA, Inc.$509Travel and LodgingCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-01-28Chiesi USA, Inc.$213Travel and LodgingCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-01-28Chiesi USA, Inc.$101Food and BeverageCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-01-28Chiesi USA, Inc.$71Travel and LodgingCash or cash equivalentFERRIPROX Drug, TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA2023
2023-01-18VERTEX PHARMACEUTICALS INCORPORATED$24Food and BeverageIn-kind items and services2023
2022-12-13Agios Pharmaceuticals, Inc.$832HonorariaCash or cash equivalentPYRUKYND Drug, Genetically Defined Disease2022
2022-12-12Agios Pharmaceuticals, Inc.$89Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2022
2022-12-08Agios Pharmaceuticals, Inc.$80Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2022
2022-10-21Agios Pharmaceuticals, Inc.$35Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2022
2022-10-20TerSera Therapeutics LLC$1,110Consulting FeeCash or cash equivalentQuzyttir Drug, Acute Care2022
2022-10-18Agios Pharmaceuticals, Inc.$147Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2022
2022-10-12GLOBAL BLOOD THERAPEUTICS, INC.$100Food and BeverageIn-kind items and servicesOXBRYTA Drug, Sickle Cell Disease2022
2022-09-07VERTEX PHARMACEUTICALS INCORPORATED$5,335Consulting FeeCash or cash equivalent2022
2022-08-20Novartis Pharmaceuticals Corporation$3,450Research paymentIn-kind items and servicesADAKVEO Biological, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH2022
2022-08-03Agios Pharmaceuticals, Inc.$142Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2022
2022-08-03Agios Pharmaceuticals, Inc.$24Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2022
2022-07-15VERTEX PHARMACEUTICALS INCORPORATED$29Food and BeverageIn-kind items and services2022
2022-07-15VERTEX PHARMACEUTICALS INCORPORATED$28Food and BeverageIn-kind items and services2022
2022-06-11VERTEX PHARMACEUTICALS INCORPORATED$46Food and BeverageIn-kind items and services2022
2022-06-10GLOBAL BLOOD THERAPEUTICS, INC.$68Food and BeverageIn-kind items and servicesOXBRYTA Drug, Sickle Cell Disease2022
2022-05-16Agios Pharmaceuticals, Inc.$1,942HonorariaCash or cash equivalentPYRUKYND Drug, Genetically Defined Disease2022
2022-05-02Novartis Pharmaceuticals Corporation$1,475Research paymentIn-kind items and servicesADAKVEO Biological, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH2022
2022-04-06Agios Pharmaceuticals, Inc.$500HonorariaCash or cash equivalentPYRUKYND Drug, Genetically Defined Disease2022
2022-03-31Novartis Pharmaceuticals Corporation$350Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentADAKVEO Biological, HEMATOLOGY2022
2022-03-31Novartis Pharmaceuticals Corporation$223Travel and LodgingIn-kind items and servicesADAKVEO Biological, HEMATOLOGY2022
2022-03-31Novartis Pharmaceuticals Corporation$12Food and BeverageIn-kind items and servicesADAKVEO Biological, HEMATOLOGY2022
2022-03-30GLOBAL BLOOD THERAPEUTICS, INC.$2,915Consulting FeeCash or cash equivalentOXBRYTA Drug, Sickle Cell Disease2022
2022-03-30GLOBAL BLOOD THERAPEUTICS, INC.$2,915Consulting FeeCash or cash equivalentOXBRYTA Drug, Sickle Cell Disease2022
2022-03-16Novartis Pharmaceuticals Corporation$64Food and BeverageIn-kind items and servicesADAKVEO Biological, HEMATOLOGY2022
2022-03-08Novartis Pharmaceuticals Corporation$610Consulting FeeCash or cash equivalentADAKVEO Biological, HEMATOLOGY2022
2022-03-02GLOBAL BLOOD THERAPEUTICS, INC.$1,855HonorariaCash or cash equivalentOXBRYTA Drug, Sickle Cell Disease2022
2022-02-11GLOBAL BLOOD THERAPEUTICS, INC.$530HonorariaCash or cash equivalentOXBRYTA Drug, Sickle Cell Disease2022
2022-01-13Novartis Pharmaceuticals Corporation$588Research paymentIn-kind items and servicesADAKVEO Drug, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH2022
2021-12-15GLOBAL BLOOD THERAPEUTICS, INC.$1,060Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-12-12GLOBAL BLOOD THERAPEUTICS, INC.$81Food and BeverageIn-kind items and servicesOXBRYTA Drug, SICKLE CELL DISEASE2021
2021-12-10Novartis Pharmaceuticals Corporation$2,440Consulting FeeCash or cash equivalentADAKVEO Biological, HEMATOLOGY2021
2021-12-10Novartis Pharmaceuticals Corporation$111Food and BeverageIn-kind items and servicesADAKVEO Biological, HEMATOLOGY2021
2021-09-30GLOBAL BLOOD THERAPEUTICS, INC.$3,180Consulting FeeCash or cash equivalentOXBRYTA Drug, SICKLE CELL DISEASE2021
2021-09-01GLOBAL BLOOD THERAPEUTICS, INC.$1,855Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-08-03Novartis Pharmaceuticals Corporation$1,264Research paymentIn-kind items and servicesADAKVEO Biological, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR ADAKVEO RESEARCH2021
2021-06-30GLOBAL BLOOD THERAPEUTICS, INC.$3,710Consulting FeeCash or cash equivalentOXBRYTA Drug, SICKLE CELL DISEASE2021
2021-05-25GLOBAL BLOOD THERAPEUTICS, INC.$64Food and BeverageIn-kind items and servicesOXBRYTA Drug, SICKLE CELL DISEASE2021
2021-02-17GLOBAL BLOOD THERAPEUTICS, INC.$795Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2020-12-17Omeros Corporation$2,800HonorariaCash or cash equivalentNarsoplimab Drug, Hematology Oncology2020
2020-12-10Novartis Pharmaceuticals Corporation$2,440Consulting FeeCash or cash equivalentADAKVEO Biological, HEMATOLOGY2020
2020-12-08Chiesi USA, Inc.$2,100Consulting FeeCash or cash equivalentFERRIPROX Drug, TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES2020
2020-11-24GLOBAL BLOOD THERAPEUTICS, INC.$1,325Consulting FeeCash or cash equivalentOXBRYTA Drug, SICKLE CELL DISEASE2020
2020-11-24GLOBAL BLOOD THERAPEUTICS, INC.$795Consulting FeeCash or cash equivalentOXBRYTA Drug, SICKLE CELL DISEASE2020
2020-09-24Novartis Pharmaceuticals Corporation$1,220Consulting FeeCash or cash equivalentADAKVEO Biological, HEMATOLOGY2020
2020-09-16GLOBAL BLOOD THERAPEUTICS, INC.$2,120Consulting FeeCash or cash equivalentOXBRYTA Drug, SICKLE CELL DISEASE2020
2020-09-15GLOBAL BLOOD THERAPEUTICS, INC.$635Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOXBRYTA Drug, SICKLE CELL DISEASE2020
2020-08-04Novartis Pharmaceuticals Corporation$3,660Consulting FeeCash or cash equivalent2020
2020-05-28GLOBAL BLOOD THERAPEUTICS, INC.$635Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOXBRYTA Drug, SICKLE CELL DISEASE2020
2019-12-05Novartis Pharmaceuticals Corporation$3,660Consulting FeeCash or cash equivalentADAKVEO Biological, HEMATOLOGY2019
2019-12-05Novartis Pharmaceuticals Corporation$116Food and BeverageIn-kind items and servicesADAKVEO Biological, HEMATOLOGY2019
2019-12-05Novartis Pharmaceuticals Corporation$70Food and BeverageIn-kind items and servicesADAKVEO Biological, HEMATOLOGY2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-11-13Novo Nordisk ASCHILDRENS RESEARCH INSTITUTE$9864202-HEM-3012025
2025-10-01Novartis Pharmaceuticals CorporationCHILDRENS NATIONAL MEDICAL CENTER$201A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizu2025
2025-09-25Novartis Pharmaceuticals CorporationChildrens Hospital$18,375A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or with2025
2025-08-21Novartis Pharmaceuticals CorporationChildrens Hospital$37,591An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N2025
2025-07-18GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$1,935AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL 2025
2025-07-18GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$14,832AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL 2025
2025-07-18GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$1,883AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL 2025
2025-07-18GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$4,515AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL 2025
2025-06-05GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$1,816AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL 2025
2025-06-05GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$1,935AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL 2025
2025-06-05GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$5,575AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL 2025
2025-04-16PFIZER INC.CHILDRENS NATIONAL MEDICAL CENTER$2,895AN OPENLABEL EXTENSION STUDY OF VOXELOTOR ADMINISTERED ORALLY TO PARTICIPANTS WITH SICKLE CELL DISEASE WHO HAVE PARTICIP2025
2025-03-01Novartis Pharmaceuticals CorporationChildrens Hospital$9,882A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizu2025
2025-01-17Novartis Pharmaceuticals CorporationChildrens Hospital$3,750A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or with2025
2025-01-14Novartis Pharmaceuticals CorporationChildrens Hospital$127,704An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N2025
2024-12-02ARENA PHARMACEUTICALS, INC.Childrens National Medical Center Hematology and Oncology$4,438A PHASE 23 RANDOMIZED MULTICENTER STUDY OF GBT021601 ADMINISTERED ORALLY TO PARTICIPANTS WITH SICKLE CELL DISEASE AND AN2024
2024-10-17Novo Nordisk ASCHILDRENS RESEARCH INSTITUTE$3,9514202-HEM-3012024
2024-10-16ARENA PHARMACEUTICALS, INC.Childrens National Medical Center Hematology and Oncology$18,594A PHASE 23 RANDOMIZED MULTICENTER STUDY OF GBT021601 ADMINISTERED ORALLY TO PARTICIPANTS WITH SICKLE CELL DISEASE AND AN2024
2024-09-11GLOBAL BLOOD THERAPEUTICS, INC.Childrens Reasearch Institute$4,750A PHASE 2A OPENLABEL SINGLE AND MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS SAFETY TOLERABILITY AND TREATMENT E2024
2024-03-04PFIZER INC.CHILDRENS RESEARCH INSTITUTE$99,691MACHINE LEARNING TO IDENTIFY CHILDREN WITH SICKLE CELL DISEASE AT HIGH RISK FOR RETURN EMERGENCY VISITS AFTER VASOOCCLUS2024
2024-01-05Novartis Pharmaceuticals CorporationChildrens Hospital$111,058An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N2024
2023-05-10Novartis Pharmaceuticals CorporationCHILDRENS HOSPITAL$146,070An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N2023
2023-03-22GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$1,250AN OPENLABEL EXPANDED ACCESS PROTOCOL FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WHO HAVE NO ALTERNATIVE TREATMENT 2023
2023-01-26Novartis Pharmaceuticals CorporationCHILDRENS HOSPITAL$33A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or with2023
2023-01-09Novartis Pharmaceuticals CorporationCHILDRENS HOSPITAL$272,008An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N2023
2023-01-04Novartis Pharmaceuticals CorporationCHILDRENS HOSPITAL$29,508A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or with2023
2022-12-27Novartis Pharmaceuticals CorporationCHILDRENS HOSPITAL$19,141AN OPEN-LABEL, MULTI-CENTER, PHASE IV, ROLLOVER STUDY FOR PATIENTS WITH SICKLE CELL DISEASE WHO HAVE COMPLETED A PRIOR N2022
2022-10-19GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$1,250GBT_GBT_PEDIATRIC_440-007_2926_012022
2022-08-23GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$2,400GBT_GBT440-038_3702_012022
2022-06-07GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$4,121GLOBA002_GBT440-032_800361312022
2022-05-05GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$4,000GLOBA002_GBT440-032_800361312022
2022-01-11Novartis Pharmaceuticals CorporationCHILDRENS HOSPITAL$242,016A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITH2022
2021-12-07GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$859GBT_GBT440-038_3702_012021
2021-10-20GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$4,260GBT_GBT440-038_3702_012021
2021-06-21GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$278GBT_GBT440-038_3702_012021
2021-06-21GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$2,408GBT_GBT440-038_3702_012021
2021-05-07GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$2,408GBT_GBT440-038_3702_012021
2021-04-19GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$1,805GBT_GBT440-038_3702_012021
2021-04-15GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$16,632GBT_GBT_PEDIATRIC_440-007_2926_012021
2021-04-15GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$5,620GBT_GBT_PEDIATRIC_440-007_2926_012021
2021-04-08GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$1,704GBT_GBT440-038_3702_012021
2021-03-10GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$3,408GBT_GBT440-038_3702_012021
2021-02-08GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$2,120GBT_GBT_PEDIATRIC_440-007_2926_012021
2021-02-05GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$1,593GBT_GBT440-038_3702_012021
2021-01-18Novartis Pharmaceuticals CorporationCHILDRENS NATIONAL HEALTH SYSTEM$389,190A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITH2021
2021-01-06GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$3,186GBT_GBT440-038_3702_012021
2020-12-08GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS NATIONAL MEDICAL CENTER$13,525GBT_GBT440-038_3702_012020
2020-10-29GLOBAL BLOOD THERAPEUTICS, INC.CHILDREN'S NATIONAL MEDICAL CENTER - WASHINGTON DC$8,420GBT_GBT_PEDIATRIC_440-007_2926_012020
2020-10-02GLOBAL BLOOD THERAPEUTICS, INC.CHILDREN'S NATIONAL MEDICAL CENTER - WASHINGTON DC$14,118GBT_GBT_PEDIATRIC_440-007_2926_012020
2020-09-02GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$1,875GBT440-0342020
2020-09-02GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$375GBT440-0342020
2020-09-02GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$1,000GBT440-0342020
2020-09-02GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$1,250GBT440-0342020
2020-09-02GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$6,250GBT440-0342020
2020-08-06GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$2,000GBT440-0312020
2020-08-06GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$375GBT440-0312020
2020-08-06GLOBAL BLOOD THERAPEUTICS, INC.CHILDRENS RESEARCH INSTITUTE$1,250GBT440-0312020
2020-07-30GLOBAL BLOOD THERAPEUTICS, INC.CHILDREN'S NATIONAL MEDICAL CENTER - WASHINGTON DC$8,858GBT_GBT_PEDIATRIC_440-007_2926_012020
2020-06-19GLOBAL BLOOD THERAPEUTICS, INC.CHILDREN?S RESEARCH INSTITUTE$15,235GBT_GBT_PEDIATRIC_440-007_2926_012020
2020-04-14Novartis Pharmaceuticals CorporationCHILDRENS NATIONAL HEALTH SYSTEM$132,668A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITH2020
2019-06-20APO-PHARMA INC.UNIV OF MI HOSPITALS & HLTH CTRS$26,762LA38-EXT2019
2019-05-24Novartis Pharmaceuticals CorporationCHILDRENS NATIONAL HEALTH SYSTEM$13,134A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITH2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Prince George's CountyLanham CDP

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Lanham, MD, county Prince George's County, MD, state Maryland; placed by its city name.

MeasurePlace (city or town)
Lanham, MD
County
Prince George's County, MD
State
Maryland
Population B0100311,433959,7546,206,011
Population, 2020 census P111,282967,2016,177,224
Median age B0100238.638.539.4
Under 18 B0100124.4%22.1%22.2%
65 and over B0100117.3%14.9%16.7%
Households B110013,183347,7442,362,928
Foreign born B0500235.0%25.3%16.6%
Median household income B19013$103,556$101,798$103,678
Median family income B19113$122,367$120,601$127,817
Per capita income B19301$35,958$46,366$52,979
Poverty rate B170017.3%10.8%9.4%
Unemployment rate B230255.4%6.4%4.9%
Civilian labor force B230255,952531,9863,313,651
Mean commute (minutes) B0801332.535.231.1
Bachelor's degree or higher B1500327.6%36.7%43.4%
Housing units B250013,405365,5062,560,784
Owner-occupied B2500376.8%62.3%67.6%
Renters B2500323.2%37.7%32.4%
Median home value B25077$436,900$426,000$419,900
Median gross rent B25064$2,050$1,799$1,705
White, not Hispanic B030024.7%10.8%46.6%
Black B0300252.6%58.2%28.9%
Hispanic or Latino B0300233.7%22.5%12.5%
Asian B030025.1%3.9%6.5%
American Indian and Alaska Native B030020.0%0.1%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Lanham, MD.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.